Üstün, C. Et Al. 2002. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia. Medical Oncology , vol.19, no.1 , 59-67.

Üstün, C., Beksac, M., DALVA, K., Koc, H., Konuk, N., İLHAN, ., ... ÖZCAN, M. E.(2002). In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia. Medical Oncology , vol.19, no.1, 59-67.

Üstün, C. Et Al. "In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia," Medical Oncology , vol.19, no.1, 59-67, 2002

Üstün, C. Et Al. "In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia." Medical Oncology , vol.19, no.1, pp.59-67, 2002

Üstün, C. Et Al. (2002) . "In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia." Medical Oncology , vol.19, no.1, pp.59-67.

@article{article, author={C. Üstün Et Al. }, title={In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia}, journal={Medical Oncology}, year=2002, pages={59-67} }